Venlafaxine HCl
Catalog No.S1441
Molecular Weight(MW): 313.86
Venlafaxine HCl is an arylalkanolamine serotonin-norepinephrine reuptake inhibitor (SNRI), used to treat major depressive disorder (MDD), generalised anxiety disorder (GAD), panic disorder and social phobia.
Purity & Quality Control
Choose Selective 5-HT Receptor Inhibitors
Biological Activity
| Description | Venlafaxine HCl is an arylalkanolamine serotonin-norepinephrine reuptake inhibitor (SNRI), used to treat major depressive disorder (MDD), generalised anxiety disorder (GAD), panic disorder and social phobia. | |
|---|---|---|
| Targets |
|
|
| In vitro |
Venlafaxine has a low potential to inhibit the metabolism of substrates for CYP2D6 such as imipramine and desipramine compared with several of the most widely used SSRIs, as well as the metabolism of substrates for several of the other major human hepatic P450s. [1] Venlafaxine inhibits binding to the human norepinephrine (NE) and serotonin (5-HT) transporters with K(i) values of 2480 nM and 82 nM, respectively, and with a K(i) ratio of 30. Venlafaxine has ED(50) values of 5.9 mg/kg and 94 mg/kg for blocking p-chloramphetamine- and 6-hydroxydopamine-induced monoamine depletion, respectively. [2] |
|
| In vivo | Venlafaxine induces a dose-dependent antinociceptive effect following i.p. administration with an ED50 of 46.7 mg/kg in mice. Venlafaxine-induced antinociception is significantly inhibited by naloxone, nor-BNI and naltrindole but not by beta-FNA or naloxonazine, implying involvement of kappa1- and delta-opioid mechanisms in mice. [3] Venlafaxine reverses hyperalgesia in rats with a fully developed neuropathic lesion. Venlafaxine also appears to have a mild non-specific analgesic effect that increased paw withdrawal latency (PWL) in the sham limb. [4] |
Protocol
Solubility (25°C)
| In vitro | DMSO | 55.5 mg/mL (176.83 mM) |
|---|---|---|
| Water | 55.5 mg/mL (176.83 mM) | |
| Ethanol | 55.5 mg/mL (176.83 mM) |
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
Chemical Information
| Molecular Weight | 313.86 |
|---|---|
| Formula | C17H27NO2·HCl |
| CAS No. | 99300-78-4 |
| Storage | powder |
| in solvent | |
| Synonyms | N/A |
Bio Calculators
Molarity Calculator
Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).
Dilution Calculator
Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:
Concentration (start) x Volume (start) = Concentration (final) x Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )
* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).
Molecular Weight Calculator
Enter the chemical formula of a compound to calculate its molar mass and elemental composition:
Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2
Instructions to calculate molar mass (molecular weight) of a chemical compound:
To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.
Definitions of molecular mass, molecular weight, molar mass and molar weight:
Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.
Molarity Calculator
Clinical Trial Information
| NCT Number | Recruitment | Conditions | Sponsor/Collaborators | Start Date | Phases |
|---|---|---|---|---|---|
| NCT03588572 | Recruiting | Subcortical Aphasia|Ischemic Stroke | Guangzhou General Hospital of Guangzhou Military Command | August 1 2018 | Not Applicable |
| NCT03588572 | Recruiting | Subcortical Aphasia|Ischemic Stroke | Guangzhou General Hospital of Guangzhou Military Command | August 1 2018 | Not Applicable |
| NCT03538691 | Recruiting | Major Depressive Disorder | Otsuka Pharmaceutical Development & Commercialization Inc. | July 13 2018 | Phase 3 |
| NCT03538691 | Recruiting | Major Depressive Disorder | Otsuka Pharmaceutical Development & Commercialization Inc. | July 13 2018 | Phase 3 |
| NCT03434041 | Recruiting | Depressive Disorder Treatment-Resistant | Janssen Research & Development LLC | May 25 2018 | Phase 3 |
| NCT03574792 | Recruiting | Stage III Cutaneous Squamous Cell Carcinoma of the Head and Neck AJCC v8|Stage IV Cutaneous Squamous Cell Carcinoma of the Head and Neck AJCC v8 | Roswell Park Cancer Institute|National Cancer Institute (NCI) | May 3 2018 | Not Applicable |
Tech Support
Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.
Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.
